Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

CorMedix (CRMD) Revenue (2016 - 2025)

CorMedix has reported Revenue over the past 12 years, most recently at $128.6 million for Q4 2025.

  • Quarterly results put Revenue at $128.6 million for Q4 2025, up 312.1% from a year ago — trailing twelve months through Dec 2025 was $311.7 million (up 616.54% YoY), and the annual figure for FY2025 was $311.7 million, up 617.03%.
  • Revenue reached $128.6 million in Q4 2025 per CRMD's latest filing, up from $104.3 million in the prior quarter.
  • Across five years, Revenue topped out at $128.6 million in Q4 2025 and bottomed at $6817.0 in Q3 2022.
  • Median Revenue over the past 4 years was $88261.0 (2021), compared with a mean of $23.7 million.
  • The largest annual shift saw Revenue plummeted 91.35% in 2022 before it surged 4829.4% in 2025.
  • Over 4 years, Revenue stood at $56397.0 in 2021, then tumbled by 47.33% to $29702.0 in 2022, then surged by 104976.31% to $31.2 million in 2024, then soared by 312.1% to $128.6 million in 2025.
  • Business Quant data shows Revenue for CRMD at $128.6 million in Q4 2025, $104.3 million in Q3 2025, and $39.7 million in Q2 2025.